Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- CheckyesterdayChange DetectedRevision label updated from v3.5.3 to v3.5.4, indicating a minor site/template update.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page revision label was updated from **v3.5.2** to **v3.5.3**, indicating a newer site/application version for the same study record.SummaryDifference0.1%

- Check29 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check58 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check79 days agoChange DetectedAdded site navigation/footer elements for Moffitt Clinical Trials, the sponsoring institution, Helpful Links, and access to drug/device information and study documents.SummaryDifference0.3%

Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.